Literature DB >> 19969063

2,3,7,8-Tetrachlorodibenzo-p-dioxin and beta-naphthoflavone induce cellular hypertrophy in H9c2 cells by an aryl hydrocarbon receptor-dependant mechanism.

Beshay N M Zordoky1, Ayman O S El-Kadi.   

Abstract

Cigarette smoke is a major risk factor for cardiovascular diseases. It contains thousands of compounds that activate the aryl hydrocarbon receptor (AhR). In addition, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), the most potent AhR ligand, has been shown to cause cardiotoxic effects in several in vivo models. Although induction of CYP1 family is the most important effect of AhR activation, the role of CYP1 induction in mediating the cardiotoxic effect of TCDD is usually overlooked. Therefore, we investigated whether AhR activation causes a hypertrophic effect in H9c2 cells and we related this effect to changes in CYP gene expression. In the current study, the cardiac derived H9c2 cells were treated with two AhR ligands, TCDD and beta-naphthoflavone (BNF), for 24 and 48h. The expression of the hypertrophic markers, atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), and several CYP genes were measured by real-time PCR. Treatment of H9c2 cells with TCDD or BNF for 24h caused a significant induction of CYP1A1, CYP1B1, and CYP4A1; however, there was no change in the expression of other genes. On the other hand, treatment of the cells with TCDD or BNF for 48h caused a significant induction of the hypertrophic markers, ANP and BNP, and several CYP genes such as CYP1A1, CYP1B1, CYP2E1, CYP2J3, and CYP4F4 parallel to a significant increase in the cell surface area. Neither TCDD nor BNF increased the oxidative stress in H9c2 cells at all concentrations tested. Interestingly, resveratrol, an AhR antagonist, protected the cells from TCDD-induced hypertrophy. In conclusion, AhR ligands caused a hypertrophic effect in H9c2 cells which was associated with induction of several CYP genes which can be prevented by resveratrol. Copyright (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19969063     DOI: 10.1016/j.tiv.2009.12.002

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  10 in total

1.  Metabolism of arachidonic acid by the cytochrome P450 enzyme in patients with chronic Keshan disease and dilated cardiomyopathy.

Authors:  Bing Zhou; Shulan He; X I Wang; Xiaolong Zhen; Xiaohui Su; Wuhong Tan
Journal:  Biomed Rep       Date:  2015-12-31

2.  Star-PAP controlled alternative polyadenylation coupled poly(A) tail length regulates protein expression in hypertrophic heart.

Authors:  A P Sudheesh; Nimmy Mohan; Nimmy Francis; Rakesh S Laishram; Richard A Anderson
Journal:  Nucleic Acids Res       Date:  2019-11-18       Impact factor: 16.971

3.  The role of cytochrome P450 1B1 and its associated mid-chain hydroxyeicosatetraenoic acid metabolites in the development of cardiac hypertrophy induced by isoproterenol.

Authors:  Zaid H Maayah; Hassan N Althurwi; Ahmed A El-Sherbeni; Ghada Abdelhamid; Arno G Siraki; Ayman O S El-Kadi
Journal:  Mol Cell Biochem       Date:  2017-03-01       Impact factor: 3.396

4.  Genetic dissection of endothelial transcriptional activity of zebrafish aryl hydrocarbon receptors (AHRs).

Authors:  Wade W Sugden; Roberto C Leonardo-Mendonça; Darío Acuña-Castroviejo; Arndt F Siekmann
Journal:  PLoS One       Date:  2017-08-17       Impact factor: 3.240

5.  Dual character of flavonoids in attenuating and aggravating ischemia-reperfusion-induced myocardial injury.

Authors:  Wenqiang Li; Yun Li; Ruifang Sun; Sumei Zhou; Meifeng Li; Mingchen Feng; Yingguang Xie
Journal:  Exp Ther Med       Date:  2017-06-26       Impact factor: 2.447

6.  Mitochondrial activity and oxidative stress functions are influenced by the activation of AhR-induced CYP1A1 overexpression in cardiomyocytes.

Authors:  Bing Zhou; Xi Wang; Feng Li; Yingting Wang; Lei Yang; Xiaolong Zhen; Wuhong Tan
Journal:  Mol Med Rep       Date:  2017-05-12       Impact factor: 2.952

Review 7.  Left Ventricular Hypertrophy: Roles of Mitochondria CYP1B1 and Melatonergic Pathways in Co-Ordinating Wider Pathophysiology.

Authors:  George Anderson; Gianluigi Mazzoccoli
Journal:  Int J Mol Sci       Date:  2019-08-20       Impact factor: 5.923

8.  CYP1B1 as a therapeutic target in cardio-oncology.

Authors:  Alexa N Carrera; Marianne K O Grant; Beshay N Zordoky
Journal:  Clin Sci (Lond)       Date:  2020-11-13       Impact factor: 6.124

9.  Development of 2-arylbenzo[h]quinolone analogs as selective CYP1B1 inhibitors.

Authors:  Jinyun Dong; Zengtao Wang; Qingqing Meng; Qijing Zhang; Guang Huang; Jiahua Cui; Shaoshun Li
Journal:  RSC Adv       Date:  2018-04-20       Impact factor: 3.361

10.  Comparison of the cytotoxic potential of cigarette smoke and electronic cigarette vapour extract on cultured myocardial cells.

Authors:  Konstantinos E Farsalinos; Giorgio Romagna; Elena Allifranchini; Emiliano Ripamonti; Elena Bocchietto; Stefano Todeschi; Dimitris Tsiapras; Stamatis Kyrzopoulos; Vassilis Voudris
Journal:  Int J Environ Res Public Health       Date:  2013-10-16       Impact factor: 3.390

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.